C Minichsdorfer1, M Hohenegger. 1. Institute of Pharmacology, Center of Biomolecular Medicine and Pharmacology, Medical University of Vienna, Waehringerstrasse 13A, Vienna, Austria.
Abstract
BACKGROUND AND PURPOSE: Beside their cholesterol lowering effect, statins exert pleiotropic effects, which include anti-inflammatory, immunosuppressive and anti-proliferative actions. In higher concentrations, statins trigger apoptosis in primary cells and tumour cells. In particular, melanoma cells have been found to be susceptible to statin-induced apoptosis, although only after longer incubation times. The molecular mechanisms behind this delayed drug-induced apoptosis are still unclear. EXPERIMENTAL APPROACH: The human melanoma A375 and 518A2 cell lines were exposed to various statins in a time-dependent and dose-dependent manner, and indicators of apoptosis, caspase activity and individual apoptotic pathways were analysed for 3-hydroxy-3-methylglutaryl-coenzyme A reductase dependent and independent effects. KEY RESULTS: Kinetic analysis of statin-induced apoptosis revealed an apoptotic burst for exposure times longer than 24 h. While the extrinsic pathway was not activated within 24 h, longer incubation times corroborated amplification of the mitochondrial pathway with significant activation of caspase 8. Continuous refreshing of the simvastatin-containing medium abrogated the mitochondrial amplification loop via caspase 8. Moreover, conditional medium, supplemented with mevalonic acid in order to nullify a possible contamination by statins, significantly triggered caspase 8 activity. Fas ligand was excluded as a possible candidate to account for the statin-induced autocrine amplification loop. CONCLUSIONS AND IMPLICATIONS: Simvastatin and atorvastatin are capable of triggering an 'autocrine' suicide factor, which amplifies apoptosis via the extrinsic pathway in human melanoma cells. This pro-apoptotic stimulus implies possible therapeutic potential and may guide feasibility for more potent statins in anti-cancer strategies.
BACKGROUND AND PURPOSE: Beside their cholesterol lowering effect, statins exert pleiotropic effects, which include anti-inflammatory, immunosuppressive and anti-proliferative actions. In higher concentrations, statins trigger apoptosis in primary cells and tumour cells. In particular, melanoma cells have been found to be susceptible to statin-induced apoptosis, although only after longer incubation times. The molecular mechanisms behind this delayed drug-induced apoptosis are still unclear. EXPERIMENTAL APPROACH: The humanmelanoma A375 and 518A2 cell lines were exposed to various statins in a time-dependent and dose-dependent manner, and indicators of apoptosis, caspase activity and individual apoptotic pathways were analysed for 3-hydroxy-3-methylglutaryl-coenzyme A reductase dependent and independent effects. KEY RESULTS: Kinetic analysis of statin-induced apoptosis revealed an apoptotic burst for exposure times longer than 24 h. While the extrinsic pathway was not activated within 24 h, longer incubation times corroborated amplification of the mitochondrial pathway with significant activation of caspase 8. Continuous refreshing of the simvastatin-containing medium abrogated the mitochondrial amplification loop via caspase 8. Moreover, conditional medium, supplemented with mevalonic acid in order to nullify a possible contamination by statins, significantly triggered caspase 8 activity. Fas ligand was excluded as a possible candidate to account for the statin-induced autocrine amplification loop. CONCLUSIONS AND IMPLICATIONS: Simvastatin and atorvastatin are capable of triggering an 'autocrine' suicide factor, which amplifies apoptosis via the extrinsic pathway in humanmelanoma cells. This pro-apoptotic stimulus implies possible therapeutic potential and may guide feasibility for more potent statins in anti-cancer strategies.
Authors: Marie-France Demierre; Peter D R Higgins; Stephen B Gruber; Ernest Hawk; Scott M Lippman Journal: Nat Rev Cancer Date: 2005-12 Impact factor: 60.716
Authors: Yiqun G Shellman; Deborah Ribble; Leslie Miller; John Gendall; Kayleen Vanbuskirk; Desiree Kelly; David A Norris; Robert P Dellavalle Journal: Melanoma Res Date: 2005-04 Impact factor: 3.599
Authors: Ellen van der Spek; Andries C Bloem; Niels W C J van de Donk; Lijnie H Bogers; René van der Griend; Mark H Kramer; Okke de Weerdt; Shulamiet Wittebol; Henk M Lokhorst Journal: Haematologica Date: 2006-04 Impact factor: 9.941
Authors: A Thibault; D Samid; A C Tompkins; W D Figg; M R Cooper; R J Hohl; J Trepel; B Liang; N Patronas; D J Venzon; E Reed; C E Myers Journal: Clin Cancer Res Date: 1996-03 Impact factor: 12.531
Authors: W S el-Deiry; J W Harper; P M O'Connor; V E Velculescu; C E Canman; J Jackman; J A Pietenpol; M Burrell; D E Hill; Y Wang Journal: Cancer Res Date: 1994-03-01 Impact factor: 12.701
Authors: Deepa Jagtap; Carol A Rosenberg; Lisa W Martin; Mary Pettinger; Janardan Khandekar; Dorothy Lane; Ira Ockene; Michael S Simon Journal: Cancer Date: 2012-03-20 Impact factor: 6.860
Authors: Christine Wasinger; Martin Künzl; Christoph Minichsdorfer; Christoph Höller; Maria Zellner; Martin Hohenegger Journal: Br J Pharmacol Date: 2014-12 Impact factor: 8.739
Authors: Elisabeth Livingstone; Loes M Hollestein; Myrthe P P van Herk-Sukel; Lonneke van de Poll-Franse; Arjen Joosse; Bastian Schilling; Tamar Nijsten; Dirk Schadendorf; Esther de Vries Journal: Cancer Med Date: 2014-06-17 Impact factor: 4.452